OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of OpGen (NASDAQ:OPGNGet Free Report) in a note issued to investors on Friday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Price Performance

NASDAQ OPGN opened at $0.34 on Friday. OpGen has a fifty-two week low of $0.17 and a fifty-two week high of $3.84. The stock has a market cap of $3.40 million, a price-to-earnings ratio of -0.05 and a beta of -0.81. The business has a fifty day moving average of $0.39 and a 200-day moving average of $0.43.

OpGen (NASDAQ:OPGNGet Free Report) last announced its earnings results on Tuesday, November 14th. The medical research company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). OpGen had a negative return on equity of 316.30% and a negative net margin of 852.18%. The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.90 million. As a group, analysts anticipate that OpGen will post -2.02 EPS for the current year.

Institutional Investors Weigh In On OpGen

Hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC grew its stake in shares of OpGen by 571.0% during the 3rd quarter. Citadel Advisors LLC now owns 100,773 shares of the medical research company’s stock valued at $29,000 after buying an additional 85,754 shares during the period. Vanguard Group Inc. increased its stake in OpGen by 39.8% during the third quarter. Vanguard Group Inc. now owns 1,877,597 shares of the medical research company’s stock worth $537,000 after acquiring an additional 534,960 shares during the last quarter. HRT Financial LP purchased a new position in shares of OpGen in the 4th quarter worth about $26,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of OpGen during the 1st quarter worth about $49,000. 13.07% of the stock is owned by institutional investors and hedge funds.

About OpGen

(Get Free Report)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Further Reading

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.